Exhaled volatile substances mirror clinical conditions in pediatric chronic kidney disease

Juliane Obermeier1, Phillip Trefz1, Josephine Happ1

  • 1Department of Anesthesiology and Intensive Care Medicine, Rostock Medical Breath Research Analytics and Technologies (ROMBAT), University Medicine Rostock, Rostock, Germany.

Plos One
|June 2, 2017
PubMed

Insights

Analyzing exhaled breath profiles in children with chronic kidney disease (CKD) revealed distinct metabolic changes. These early breath biomarkers indicate metabolic adaptation occurs even in mild CKD stages, offering a non-invasive monitoring approach.

Area of Science:

  • Biochemistry
  • Pediatric Nephrology
  • Analytical Chemistry

Background:

  • Monitoring metabolic adaptation in pediatric chronic kidney disease (CKD) is challenging.
  • Non-invasive breath analysis offers a promising avenue for pediatric patient monitoring.
  • Limited data exists on exhaled breath profiles in children with CKD.

Purpose of the Study:

  • To investigate exhaled volatile organic compound (VOC) profiles in pediatric CKD patients and kidney transplant recipients.
  • To identify potential breath biomarkers for early detection of metabolic changes in pediatric CKD.
  • To correlate breath profiles with CKD stage, underlying renal disease, and transplant status.

Main Methods:

  • Quantitative analysis of exhaled breath profiles using proton-transfer-reaction time-of-flight mass spectrometry (PTR-ToF).
  • Study included 116 pediatric subjects: 48 with mild-to-moderate CKD, 8 with kidney transplants (KTx), and 60 healthy controls.
  • Analysis considered CKD stage, renal disease type (HUS, glomerular, etc.), and transplant status as classifiers.

Main Results:

  • Distinct exhaled VOC patterns were observed between CKD/KTx patients and healthy children.
  • Elevated levels of ammonia, ethanol, isoprene, pentanal, and heptanal, and lower methylamine were found in patients.
  • Ammonia accumulation was detected in CKD stage 1; alterations in isoprene, pentanal, and heptanal appeared in stages 2-4.

Conclusions:

  • Non-invasive breath testing can reveal early metabolic adaptations in pediatric CKD.
  • Specific VOCs like ammonia, isoprene, pentanal, and heptanal may serve as early biomarkers for CKD progression.
  • Breath analysis holds potential for understanding disease mechanisms and guiding clinical management in pediatric kidney disease.

Related Concept Videos

Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
807
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
341
Acute Kidney Injury III: Clinical Manifestations01:29

Acute Kidney Injury III: Clinical Manifestations

Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
1.1K
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
544
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
865
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
489